Immunaktive Wirkung von Mistellektin I in Abhängigkeit von der Dosierung

Journal/Book: Arzneim.-Forsch./Drug Res. 44 (11), 11, 1255-1258. 1994;

Abstract: Galactoside-specific mistletoe lectin-1 (ML-1) was isolated by affinitychromatography from proprietary mistletoe extract and checked inBALB/c-mice for its immunoactive potency. To investigate the optimalimmunomodulating dosage, ML-1 (0.5, 1.0, 2.5, 5.0 ng/kg body weight,b.w.) was subcutaneously administered for three subsequent days followedby another injection 48 h later. These studies proved that injections of1 ng ML-1/kg b.w. induced optimal immunomodulation, since thymocyteproliferation, maturation and emigration were significantly enhanced inthis murine model as compared to non-treated control mice. Further on,counts of peripheral blood lymphocytes and monocytes as well asexpression of relevant activation markers on these cells revealedsignificant increases after ML-1 (1 ng/kg b.w.) administration. However,increase of cell counts and activity of peritoneal macrophages were lesspronounced but still statistically significant for this ML-1concentration. Determination of immune responses after low dose ML-1treatment (0.5 ng/kg b.w.) presented relevant (partly statisticallysignificant) increases, too. However, high dose ML-1 treatment (2.5, 5.0ng/kg b.w.) did not enhance (but suppress) relevant immune functions.For future clinical/therapeutical treatment strategies, ML-1 dosagesranging from 0.5-1.0 ng/kg b.w. may be supposed to be optimal. Author.

Keyword(s): ADJUVANTS-IMMUNOLOGIC/IP (isolation & purification)

Zurück | Weiter